Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
CYC
vs
S
S&P/ASX 300
Over the past 12 months, CYC has underperformed S&P/ASX 300, delivering a return of -28% compared to S&P/ASX 300's 1% drop.
Stocks Performance
CYC vs S&P/ASX 300
Performance Gap
CYC vs S&P/ASX 300
Performance By Year
CYC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cyclopharm Ltd
Glance View
Cyclopharm Ltd is a medical technology company best known for Technegas, a lung-imaging product used with nuclear medicine scans. It makes and sells equipment and related consumables that help doctors see how air moves through the lungs, which is useful for checking suspected blood clots, COPD, asthma, and other breathing problems. The company also supports hospitals and imaging centers with service, training, and product maintenance. Its main customers are hospitals, nuclear medicine departments, and imaging clinics. Cyclopharm earns money by selling Technegas systems, the materials used to run the scans, and ongoing support tied to those systems. This gives it a mix of one-time equipment sales and repeat revenue from consumables and services. What makes the business different is that it sits in a narrow part of the healthcare market where a specific diagnostic tool is needed rather than a broad catalog of medical products. That focus makes Cyclopharm closely tied to clinical imaging workflows and the specialists who perform them, so its value comes from helping medical teams produce clearer lung scans with a dedicated product rather than a general-purpose device.